Study identifier:D589BL00022
ClinicalTrials.gov identifier:NCT01415518
EudraCT identifier:N/A
CTIS identifier:N/A
Efficacy and tolerability study of Symbicort Turbuhaler(160/4.5µg/inhalation,2inhalations twice daily) added to Atrovent (20µg/inhalation, 2 inhalations 4 times daily)+theophylline SR(0.1g/tablet,1 tablet p.o. twice daily) compared with Atrovent+theophylline SR in severe COPD patients.
Chronic obstructive pulmonary disease (COPD)
Phase 4
No
Drug: Budesonide/formoterol (Symbicort Turbuhaler, Drug: ipratropium (AtroventTM), theophylline SR
All
581
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jun 2019 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Other: 1 budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) | Drug: Drug: Budesonide/formoterol (Symbicort Turbuhaler budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) Drug: Drug: ipratropium (AtroventTM) ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) Drug: theophylline SR theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) |
Other: 2 ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) | Drug: Drug: ipratropium (AtroventTM) ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) Drug: theophylline SR theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily) |